Rex A. Parker

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Masato Furuhashi, Gürol Tuncman, Cem Z. Görgün et al. · Nature · 2007 · 730 citations · Full text

Medicine, Biochemistry, Pharmacology +12

Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis

Liza Makowski, Jeffrey B. Boord, Kazuhisa Maeda et al. · Nature Medicine · 2001 · 691 citations

Life Sciences, Biochemistry, Immunology +12

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes

Kazuhisa Maeda, Haiming Cao, Keita Kono et al. · Cell Metabolism · 2005 · 489 citations · Full text

Life Sciences, Cell Biology, Physiology +16

Hypocholesterolemic activity of synthetic and natural tocotrienols.

Bradley C. Pearce, Rex A. Parker, Michael E. Deason et al. · Journal of Medicinal Chemistry · 1992 · 295 citations

Life Sciences, Biochemistry, Pharmacology +8